This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McClean, D. R. Articles by Crozier, I. G. Search for Related Content PubMed PubMed Citation Articles by McClean, D. R. Articles by Crozier, I. G.

The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure

^a Department of Cardiology, Christchurch Hospital, Christchurch, New Zealand

View larger version (26K): [in a new window]   Figure 1 Graph showing the change in ANP and cGMP over 24 h for each group after the initial dose of omapatrilat (A) and after the final dose of omapatrilat at 12 weeks (B). Data represent mean values ± SEM. *p < 0.05. **p < 0.01 vs. 2.5-mg low dose control group.